The EMA plays a significant role in addressing neonatal disorders through various initiatives. These include the approval of medicines specifically designed for neonates, the establishment of guidelines for clinical trials involving neonates, and the implementation of pharmacovigilance activities to monitor the safety of these medicines. The EMA's work ensures that neonates receive the best possible care with the most appropriate therapeutic options.
